Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Micromedic Technologies


11 Feb 2016 - 12 Feb 2016
18 Feb 2016 - 20 Feb 2016
25 Feb 2016 - 26 Feb 2016

First US FDA-Cleared Dengue Test Independently Evaluated for Detection Quality

By Labmedica International staff writers
Posted on 16 Jul 2013
Print article
Image: The dengue virus (DENV) Detect IgM Capture ELISA from InBios (Photo courtesy of Inbios).
Image: The dengue virus (DENV) Detect IgM Capture ELISA from InBios (Photo courtesy of Inbios).
Researchers have now reported results from a first evaluation of the FDA-cleared assay for diagnosis of dengue virus infection in patients with suggestive clinical symptoms.

A study from the laboratory of Prof. Vivek R. Nerurkar at the University of Hawaii at Manoa (UHM; Honolulu, Hawaii, USA) provides the first independently funded evaluation of the InBios "DENV Detect IgM Capture ELISA", a rapid in vitro assay based on technology patented by the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA). The assay, produced by Inbios International, Inc. (Seattle, WA, USA), is currently the only commercially available dengue infection assay cleared by the the US Food and Drug Administration (FDA; Silver Spring, MD, USA).

Diagnostic testing for dengue virus (DENV) infection is often time-consuming and complicated. The current study provides a comparative evaluation of the rapid (about five hours) InBios assay and a 2–3 day in-house "gold-standard" assay, and discusses some of the complicating factors. Well-characterized clinical serum samples obtained from 79 dengue-infected patients or suspected cases were performance-tested for qualitative detection of anti-DENV IgM antibodies, mainly in terms of sensitivity and specificity. The serum samples were collected from Hawaii, Vietnam, Niue, Singapore, and American Samoa, where dengue outbreaks have occurred in the past. Samples with equivocal results were repeated in duplicate, and samples that remained equivocal were further examined (e.g., using plaque reduction neutralization test (PRNT) where sufficient sample serum was available). Inclusion of positive as well as negative antigens was critical for interpretation of the results, as they detect background, nonspecific reactivity.

Sensitivity and specificity of InBios ELISA compared to the in-house "gold standard" ELISA were 92% and 94%, respectively. Out of the 79 serum samples tested, 22 samples were positive and 50 samples were negative by using both assays. Levels of agreement as defined by kappa values were also determined and the two assays showed near perfect agreement (κ = 0.87).

Overall, despite the relatively minor limitations of the study itself, the results indicate that the more rapid InBios DENV Detect IgM Capture ELISA is a reliable, sensitive, and specific serological test for detection of acute or recent dengue infections. It can also be used by public health laboratories for rapid confirmation of dengue cases during dengue outbreaks. Both tests show some cross-reactivity with West Nile and other closely related viruses and this must be considered, particularly when working in geographic regions where multiple flaviviruses co-circulate.

This study by Namekar M., et al. was published online ahead of print July 3, 2013, in the Journal of Clinical Microbiology.

Related Links:

UHM Dengue Test Publication Link
University of Hawaii at Manoa

Print article



view channel
Image: Micrograph of prostatic adenocarcinoma with perineural invasion, conventional (acinar) type, the most common form of prostate cancer. Prostate biopsy, H&E stain (Photo courtesy of Nephron and Wikimedia).

Reduced PSA Screening May Delay Treatment for Earlier Onset Prostate Cancers

The recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for 2.5 years. The number of prostate needle biopsies (PNB) has been reduced and... Read more

Industry News

view channel
Image: The new CE-marked “illumigene Malaria” DNA amplification assay for detection of Plasmodium spp. DNA in human whole blood samples (Photo courtesy of Meridian Bioscience).

Collaboration Helps Accelerate Launch of New Malaria Test

The recent launch of a new in vitro diagnostic (IVD) assay, CE-marked for detection of Plasmodium spp. DNA in whole blood samples, was accomplished on an accelerated schedule via collaboration with “lean... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.